Drugs News and Research

RSS

IU scientists find evidence that invisible war between microorganisms may affect human health

Health experts have warned for years that the overuse of antibiotics is creating "superbugs" able to resist drugs treating infection.

31 Jul 2015

Psychotropic medication use widespread among older adults, new study finds

Older Americans receive prescriptions for mental health medications at more than twice the rate that younger adults do, a new study finds.

31 Jul 2015

Study sheds light on certain antagonist drugs that block physiological responses

Members of the Consolidated Research Group of Molecular Neurobiology of the Department of Biochemistry and Molecular Biology of the University of Barcelona (UB), affiliated with the Centre for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), have published a study in the journal Proceedings of the National Academy of Sciences (PNAS) about the formation of G protein-coupled receptors (GPCRs) which allows understanding the unexpected behaviour of some antagonists that block physiological responses.

30 Jul 2015

Plants send out stress signals normally associated with animals

University of Adelaide research has shown for the first time that, despite not having a nervous system, plants use signals normally associated with animals when they encounter stress.

30 Jul 2015

Commonly prescribed drug also lowers blood pressure when combined with diuretic

With the growth of electronic medical records, research utilizing data from a large number of patients, known as big data studies, can provide important information which may be unattainable via clinical trials which tend to be costly, time-consuming and involve fewer patients.

30 Jul 2015

Detailed molecular analyses reveal new treatment options for aggressive childhood leukemia

Acute lymphoblastic leukemia (ALL) leukemia is the most common type of cancer in children. It can occur in various forms, differing not only by specific changes in the genetic material of the leukemia cells but also by their response to therapies. Now, an international team of scientists from Berlin, Düsseldorf, Hannover, Heidelberg, Kiel, and Zurich have succeeded in decoding the molecular characteristics of an as yet incurable subtype of leukemia, paving the way for new therapeutic approaches.

30 Jul 2015

NEJM publishes positive clinical results from Phase 2 clinical study of volanesorsen

Isis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, and Akcea Therapeutics, its wholly owned subsidiary, announced today that The New England Journal of Medicine (NEJM) has published positive clinical results from a Phase 2 clinical study evaluating volanesorsen (formerly ISIS-APOCIII Rx) in patients with very high to severely high triglycerides.

30 Jul 2015

UIC, Northwestern University researchers create first artificial ribosome

Researchers at the University of Illinois at Chicago and Northwestern University have engineered a tethered ribosome that works nearly as well as the authentic cellular component, or organelle, that produces all the proteins and enzymes within the cell. The engineered ribosome may enable the production of new drugs and next-generation biomaterials and lead to a better understanding of how ribosomes function.

30 Jul 2015

UT Southwestern's Pulmonary Hypertension Program continues to grow in the U.S.

When Derrik Neal began having trouble breathing, he initially assumed it was because he was overweight. But after blacking out several times, he learned he had idiopathic pulmonary hypertension. Survival rates at the time he was diagnosed were five years or less - three or less if undetected.

30 Jul 2015

Discovery paves way for new therapeutic approaches to treat fatal leukemia in children

Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children. It can occur in various forms, differing not only by specific changes in the genetic material of the leukemia cells but also by their response to therapies.

30 Jul 2015

Natural protein fragment produced in the brain can inhibit enzyme implicated in Alzheimer's disease

For the first time, UCLA researchers have shown that a natural protein fragment produced in the brain can act as an inhibitor of a key enzyme implicated in the onset of Alzheimer's disease, a finding that could lead to the development of new drugs to treat the disease.

30 Jul 2015

Mice without specific brain chemical develop characteristics similar to bipolar disorder, shows study

Mice that have a particular brain chemical switched off become hyperactive and sleep for just 65 per cent of their normal time.

29 Jul 2015

World Health Organization recognizes unique pharmacological nature of Can-Fite's CF101, grants new generic name

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced that the World Health Organization's International Nonproprietary Name group has accepted the proposed generic name "piclidenoson" for its lead drug candidate, CF101.

29 Jul 2015

LixiLan-O Phase III clinical trial meets primary endpoint in patients with type 2 diabetes

Sanofi announced today that the LixiLan-O Phase III clinical trial met its primary objective in patients with type 2 diabetes treated with metformin. The fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide, a GLP-1 RA, demonstrated statistically superior reduction in HbA1c (average blood glucose over the previous three months) compared with lixisenatide and compared with insulin glargine 100 units/mL.

29 Jul 2015

RepliCel Life Sciences announces final design specifications for next-generation dermal injector

RepliCel Life Sciences Inc., a clinical stage regenerative medicine company, is pleased to announce that the final design specifications of its next-generation dermal injector (RCI-02) have been locked. Prototypes for industrial and regulatory testing will now be built to prepare for an application for CE mark clearance to market the injector in Europe in 2016.

29 Jul 2015

PDL BioPharma signs revenue interest assignment agreement with ARIAD Pharmaceuticals

PDL BioPharma, Inc. today announced that it has entered into a revenue interest assignment agreement (the "Agreement") in which it has agreed to provide ARIAD Pharmaceuticals, Inc. with up to $200 million in revenue interest financing in exchange for royalties on the net revenues of Iclusig (ponatinib).

29 Jul 2015

Study reveals that firms 'underinvest' in long-term research to develop cancer-fighting drugs

Pharmaceutical firms "underinvest" in long-term research to develop new cancer-fighting drugs due to the greater time and cost required to conduct such research, according to a newly published study co-authored by MIT economists.

29 Jul 2015

Hospitals can make patients sick, reveals Consumer Reports

Hospitals are thought to be sterile, safe environments where sick people get better, not sicker. But that's not always the case according to a new investigation by Consumer Reports into hospital-acquired infections.

29 Jul 2015

New tool combines drugs to target kinase dependency in cancer

Targeted therapies attack a cancer's genetic sensitivities. However, it can be difficult to discover the genetics driving a patient's cancer, and the effects of drugs designed to target a genetic abnormality often go beyond their intended target alone. The result is threefold: sometimes a drug is prescribed to treat a target that proves to be irrelevant to the disease, sometimes an existing drug could be used to treat a cancer for which there is no approved targeted therapy, and sometimes a combination of targeted treatments could be used to simultaneously silence more than one genetic cause of a patient's cancer.

29 Jul 2015

New analysis examines pharmacy expenditures for publicly insured children with serious chronic illness

In an analysis of expenditures for outpatient pharmacy products used by publicly insured children with serious chronic illness in California, treating hemophilia accounted for about 40 percent of expenditures but included just 0.4 percent of the group studied, suggesting a need to improve pricing for this and other effective yet high-cost medications, according to a study in the July 28 issue of JAMA.

29 Jul 2015

Drugs News and Research

IU scientists find evidence that invisible war between microorganisms may affect human health

Psychotropic medication use widespread among older adults, new study finds

Study sheds light on certain antagonist drugs that block physiological responses

Plants send out stress signals normally associated with animals

Commonly prescribed drug also lowers blood pressure when combined with diuretic

Detailed molecular analyses reveal new treatment options for aggressive childhood leukemia

NEJM publishes positive clinical results from Phase 2 clinical study of volanesorsen

UIC, Northwestern University researchers create first artificial ribosome

UT Southwestern's Pulmonary Hypertension Program continues to grow in the U.S.

Discovery paves way for new therapeutic approaches to treat fatal leukemia in children

Natural protein fragment produced in the brain can inhibit enzyme implicated in Alzheimer's disease

Mice without specific brain chemical develop characteristics similar to bipolar disorder, shows study

World Health Organization recognizes unique pharmacological nature of Can-Fite's CF101, grants new generic name

LixiLan-O Phase III clinical trial meets primary endpoint in patients with type 2 diabetes

RepliCel Life Sciences announces final design specifications for next-generation dermal injector

PDL BioPharma signs revenue interest assignment agreement with ARIAD Pharmaceuticals

Study reveals that firms 'underinvest' in long-term research to develop cancer-fighting drugs

Hospitals can make patients sick, reveals Consumer Reports

New tool combines drugs to target kinase dependency in cancer

New analysis examines pharmacy expenditures for publicly insured children with serious chronic illness

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News